Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of mild to moderate Crohn's disease for at least 3 months.~* Screening CDAI between \>150 and ≤ 250 based on subject recall.~* Average of greater than two liquid or soft stools per day and an abdominal pain intensity score \>1.~* Subject has at least one positive biomarker of inflammation: fecal calprotectin \>100 µg/g; elevated C-reactive protein (CRP) \>2 mg/dL.~Exclusion Criteria:~* Positive stool test for pathogenic bacteria including Clostridium difficile or O\&P.~* Confirmed intestinal stricture with obstructive-like clinical symptoms.~* Bowel resection within the previous 6 months.~* Change in medical therapy: must have been on a stable dose of~  * corticosteroids (prednisone or prednisolone) less than or equal to 20 mg per day for 2 weeks prior to screening,~ * budesonide less than or equal to 9 mg per day for 2 weeks prior to screening,~ * 5-aminosalicylates for 2 weeks prior to screening, and~ * immunomodulators for 6 weeks prior to screening.~* Taking greater than 20 mg per day of a corticosteroid (prednisone or prednisolone) or greater than 9 mg of budesonide.~* Received biologic therapy in past 2 years.~* Diagnosis of one or more co-morbid condition (s) requiring medical or surgical therapy that may affect bowel function, gastrointestinal symptoms.~* Serious infection in the 3 months prior to enrollment.~* Allergy or intolerance to beef or to any ingredient used in the product.~* Participated in an investigational drug or device study within 30 days.~* Does not have access to the internet.~* Taken EnteraGam®

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SBI 10 g BID (Type: ACTIVE_COMPARATOR): Serum-derived Bovine Immunoglobulin / Protein Isolate (SBI) 10.0 grams twice per day
- Placebo BID (Type: PLACEBO_COMPARATOR): Placebo w/control protein

Based on this trial design, predict the completion outcome and termination type (if applicable).